Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 18 years or above~2. Subjects must be diagnosed with cancer.~3. Subjects must experience persistent pain associated with cancer, and the pain score assessed by NRS should be \<4 within 1week before screening.~4. In the past 7 days, the subject must experience an average of 1 to 4 episodes of breakthrough cancer pain per day,The breakthrough cancer pain score should be ≥4 assessed by NRS~5. ECOG status of 0 to 2.~6. Subjects must consent to take adequate contraception during the study and 1 months after the study. Women of childbearing potential must show negative in the pregnancy test before dosing.~7. The subject must be able to understand the requirements of the study and provide a written informed consent.~Exclusion Criteria:~1. History or suspected allergies to fentanyl.~2. HGB \< 80 g/L, NEUT ≤1.0 × l09/L, PLT ≤50 × l09/L；ALT and AST higher than 3 times of ULN;total bilirubin and Cr higher than 1.5 times of ULN;PaO2 \<95%;FEV1/FVC\<70% and FEV1 accounted for less than 80% of the predicted value.~3. Any uncontrolled disease (e.g., severe mental, neurological, infectious, cardiovascular, respiratory and other systemic diseases).~4. Tumor infiltration to central nervous system.~5. Subjects are not able to slef evaluate pain intensity using NRS~6. Receive surgery in past 3 weeks~7. Treatment with any form of radiotherapy winth 1week prior to study entry that could alter pain or response to pain medication.~8. Taking monoamine oxidase inhibitors(MAOIs), CYP3A4 inhibitors or inducers within 14 days of the screening~9. Participated in other clinical trials in past 1months.~10. Pregnancy and breast-feeding women, women of childbearing age ready to conceive, and pregnancy test positive.~11. Other conditions that may affect the informed consent, compliance with the protocol, study results and safety of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled fentanyl aerosol (Type: EXPERIMENTAL): Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with Inhaled fentanyl aerosol (25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25µg) in a random sequence
- Placebo (Type: PLACEBO_COMPARATOR): Participants were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence

Based on this trial design, predict the completion outcome and termination type (if applicable).